F03 - Chronic Kidney Disease in Type 2 Diabetes: An Update for the Diabetes Care and Education Specialist

Friday, August 12, 2022

9:45 AM – 10:30 AM ET

Location: Room 314

CE/CME Hours: 0.75

CE/CME Hours: 0.75
Pharmacology Hours: 0.50
Activity Type: Knowledge-based
UAN: JA4008258-0000-22-092-L01-P
CHES/MCHES: 0.75

This session will review newly approved medications to mitigate kidney risk in people with T2D and chronic kidney disease (CKD). Case vignettes will be utilized to apply current guidelines for the treatment of CKD in T2D and discuss the role of the DCES in optimizing CKD outcomes.

Primary Presenter(s)

Sara W. Reece, PharmD, CDCES, BC-ADM, BCACP, FADCES, FCCP

Associate Professor, Pharmacy Practice; Director of IPE, SOP
PCOM Georgia SOP
Gainesville, Georgia

Disclosure: NovoNordisk (Consultant / Advisory Board)Sanofi (Consultant / Advisory Board)

PDF

Co-Presenter(s)

Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP

Vice-Chair and Professor
Washington State University, Washington

Disclosure: Dexcom (Speaker/Honoraria)Sanofi (Consultant / Advisory Board)

Moderator(s)

Katherine O'Neal, PharmD, MBA, BCACP, CDCES, BC-ADM, AE-C, CLS, FADCES

Associate Professor
University of Oklahoma College of Pharmacy
Edmond, Oklahoma

Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.